Overview

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.
Phase:
Phase 1
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
AstraZeneca
Treatments:
Acalabrutinib